FrancophonIA/ELRC3.0 huggingface dataset:
English: Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark Europe unless your doctor tells you to.
Estonian: Olanzapine Glenmark Europe ööpäevane annus on 5 mg kuni 20 mg. Sümptomite taastumisel konsulteerige oma arstiga, kuid ärge katkestage Olanzapine Glenmark Europe võtmist ilma arsti korralduseta.
English: Olanzapine Glenmark Europe 20 mg orodispersible tablets Olanzapine
Estonian: Olanzapine Glenmark Europe 20 mg suus dispergeeruvad tabletid
English: Talk to your doctor or pharmacist before you take Olanzapine Glenmark Europe - The use of Olanzapine Glenmark Europe in elderly patients with dememtia is not recommended as it may have serious side effects.
Estonian: - Olanzapine Glenmark Europe't ei soovitata anda dementsetele eakatele patsientidele, sest neil võivad tekkida tõsised kõrvaltoimed.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 5 mg olanzapine.
Estonian: TOIMEAINE(TE) SISALDUS Iga suus dispergeeruv tablett sisaldab 5 mg olansapiini.
English: Olanzapine Glenmark Europe 5mg is supplied as: yellow coloured circular flat bevelled edge orodispersible tablets with ‘B' debossed on one side.
Estonian: Kuidas Olanzapine Glenmark Europe välja näeb ja pakendi sisu Olanzapine Glenmark Europe 5 mg on saadaval: kollast värvi ringikujuliste lamedate kaldservaga suus dispergeeruvate tablettidena, mille ühele küljele on pressitud „B”.
English: 3 Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high
Estonian: 4 Täheldati esialgsete normaalsete tühja kõhu tasemete (< 5,56 mmol/l) puhul, mis tõusid kõrgeks
English: Olanzapine Glenmark Europe 5 mg orodispersible tablets Olanzapine
Estonian: Olanzapine Glenmark Europe 5 mg suus dispergeeruvad tabletid
English: Olanzapine Glenmark Europe 10 mg orodispersible tablets Olanzapine
Estonian: Olanzapine Glenmark Europe 10 mg suus dispergeeruvad tabletid
English: Fatigue Oedema Pyrexia10
Estonian: Asteenia Väsimus Tursed Püreksia10
English: Abdominal distension9
Estonian: Amneesia9 Düsartria
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 20 mg orodispersible tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 20 mg suus dispergeeruvad tabletid
English: Olanzapine Glenmark Europe 15 mg orodispersible tablets Olanzapine
Estonian: Olanzapine Glenmark Europe 15 mg suus dispergeeruvad tabletid
English: Increased alkaline phosphatase10
Estonian: Eosinofiilia Leukopeenia10 Neutropeenia10
English: Respiratory, thoracic and mediastinal disorders Epistaxis9
Estonian: Respiratoorsed , rindkere ja mediastiinumi häired
English: Yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘E' debossed on other side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „4”.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 10 mg orodispersible tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 10 mg suus dispergeeruvad tabletid Olanzapinum
English: General disorders and administration site conditions Asthenia
Estonian: Üldised häired ja manustamiskoh a reaktsioonid
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 15 mg orodispersible tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 15 mg suus dispergeeruvad tabletid
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 10 mg orodispersible tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 10 mg suus dispergeeruvad tabletid
English: 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥
Estonian: 13 Pärast lühiajalist ravi (keskmine kestvus 22 päeva), oli kehakaalutõus ≥ 7% esialgsest kehakaalust
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 15 mg orodispersible tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 15 mg suus dispergeeruvad tabletid Olanzapinum
English: Other medicines and Olanzapine Glenmark Europe Only take other medicines while you are on Olanzapine Glenmark Europe if your doctor tells you that you can. You might feel drowsy if Olanzapine Glenmark Europe is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).
Estonian: Muud ravimid ja Olanzapine Glenmark Europe Olanzapine Glenmark Europe't kasutades võite teisi ravimeid võtta ainult siis, kui teie arst on seda lubanud.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 5 mg orodispersible tablets
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 5 mg suus dispergeeruvad tabletid
English: Yellow coloured circular flat bevelled edge tablets with ‘OL' debossed on one side and ‘D' debossed on one side.
Estonian: Kollast värvi ringikujulised lamedad kaldservaga tabletid, mille ühele küljele on pressitud „OL” ja teisele küljele on pressitud „6”.
English: NAME OF THE MEDICINAL PRODUCT Olanzapine Glenmark Europe 5 mg orodispersible tablets Olanzapine
Estonian: RAVIMPREPARAADI NIMETUS Olanzapine Glenmark Europe 5 mg suus dispergeeruvad tabletid Olanzapinum
English: Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (≥ 0.01% and < 0.1%) when olanzapine is stopped abruptly.
Estonian: Olansapiinravi järsul katkestamisel on väga harva (≥ 0,01% ja < 0,1%) teatatud ägedatest sümptomitest nagu higistamine, unetus, treemor, ärevus, iiveldus või oksendamine.
English: Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
Estonian: Selles patsiendirühmas täheldati seoses olansapiini kasutamisega väga sagedaste kõrvaltoimetena ebakindlat kõnnakut ja kukkumisi.
English: Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and < 0.1%) when olanzapine is stopped abruptly.
Estonian: Olansapiinravi järsul katkestamisel on harva (≥ 0,01% ja < 0,1%) teatatud ägedatest sümptomitest nagu higistamine, unetus, treemor, ärevus, iiveldus või oksendamine.
English: Oedema
Estonian: Unisus
English: Breast feeding
Estonian: Ainevahetusja toitumishäired
English: LIST OF EXCIPIENTS
Estonian: Erektsioonihäir ed meestel
English: Neutropenia10
Estonian: Epistaksis9
English: Microcrystalline cellulose
Estonian: Ventrikulaarne tahhükardia/fibrillats ioon
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23 June 2017
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23.
English: EMA/393395/2017 EMEA/H/C/004455
Estonian: juuni 2017 EMA/393395/2017 EMEA/H/C/004455
English: What is Zafiride?
Estonian: Mis on Zafiride?
English: The CHMP noted there was inadequate information in several areas of the application, including on the manufacture of the medicine, its testing in humans and animals and its safety.
Estonian: Inimravimite komitee märkis, et müügiloa taotluse mitmes punktis puudus vastav teave, sealhulgas seoses ravimi tootmisega, selle katsetamisega inimestel ja loomadel ning ohutusega.
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that it would be unable to provide requested data on the medicine's manufacture within the required time frame.
Estonian: Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et tal ei ole võimalik ettenähtud tähtpäevaks esitada nõutud andmeid ravimi tootmise kohta.
English: How does Zafiride work?
Estonian: Kuidas Zafiride toimib?
English: Once attached to these receptors, it damages the walls of the blood vessels supplying the tumours, thereby helping to slow down the growth of the cancer.
Estonian: Neile retseptoritele kinnitudes kahjustab toimeaine kasvajat varustavate veresoonte seinu ja aeglustab seeläbi kasvaja kasvu.
English: The medicine was intended for those patients whose cancer has worsened within 6 months of treatment with cancer medicines including pemetrexed.
Estonian: Ravimit kavatseti kasutada patsientidel, kelle vähk on pärast 6 kuud ravi vähiravimitega (sh pemetrekseed) progresseerunud.
English: On 1 June 2017, MolMed S.p.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Zafiride for the treatment of advanced malignant pleural mesothelioma.
Estonian: teatas 1. juunil 2017 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Zafiride müügiloa taotlus.
English: With regard to the medicine's effectiveness, the main study did not show convincingly that Zafiride was better than placebo at prolonging lives in the intended patients.
Estonian: Mis puudutab ravimi efektiivsust, siis ei tõendanud põhiuuring veenvalt Zafiride paremust võrreldes platseeboga kavandatava patsiendirühma elumuse pikendamisel.
English: Zafiride was compared with placebo (a dummy treatment), and all patients in the study had previously been treated with pemetrexed-based chemotherapy.
Estonian: Zafiridet võrreldi platseeboga (näiv ravim) ning kõik uuringus osalenud patsiendid olid saanud varem pemetrekseedil põhinevat keemiaravi.
English: Zafiride is a medicine containing the active substance NGR-human tumour necrosis factor alpha.
Estonian: Zafiride on ravim, mille toimeaine on NGRiga liidetud inimese kasvaja nekroositegur-alfa.
English: What was Zafiride expected to be used for?
Estonian: Milleks kavatseti Zafiridet kasutada?
English: The active substance in Zafiride is thought to work by attaching to targets called CD13 and TNF receptors, found on new blood vessels forming around tumours.
Estonian: Zafiride toimeaine kinnitub arvatavalt CD13 ja TNFi retseptoritele, mida leidub kasvajate ümber moodustuvates uutes veresoontes.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Zafiride did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ravimi Zafiride kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: The company's application included results from a main study in 400 patients which looked at how long patients lived when treated with Zafiride in combination with other cancer medicines.
Estonian: Ettevõte esitas oma taotluse toetuseks andmed põhiuuringust, milles vaadeldi 400 patsiendi elumust Zafiride ja muude vähiravimite kombinatsioonraviga.
English: Based on the review of the data, at the time of the withdrawal, the CHMP had concerns and was of the provisional opinion that Zafiride could not be approved for the second-line treatment of advanced malignant pleural mesothelioma in patients whose disease had worsened within 6 months of treatment with pemetrexed.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Zafiride kasutamist pleura kaugelearenenud maliigse mesotelioomi teise valiku raviks patsientidel, kelle haigus oli progresseerunud pärast 6 kuud kestnud ravi pemetrekseediga, ei ole võimalik heaks kiita.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate use programmes using Zafiride.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Zafiride kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente.
English: Zafiride was expected to be used for treating adults with advanced malignant pleural mesothelioma, a cancer of the lining of the lungs usually caused by exposure to asbestos.
Estonian: Zafiridet kavatseti kasutada pleura kaugelearenenud maliigse mesotelioomi (vähk, mida tavaliselt põhjustab kokkupuude asbestiga) raviks täiskasvanutel.
English: Zafiride was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 3 June 2008 for malignant mesothelioma.
Estonian: Zafiride nimetati 3. juunil 2008 maliigse mesotelioomi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: The usual recommended infusion time is approximately 60 minutes.
Estonian: Tavaline soovitatav infusiooniaeg on ligikaudu 60 minutit.
English: Here are some of the main results from these studies:
Estonian: Nende uuringute põhitulemused on järgmised.
English: What measures are being taken to ensure the safe and effective use of Vectibix?
Estonian: Mis meetmed võetakse, et tagada Vectibixi ohutu ja efektiivne kasutamine?
English: Further information on Vectibix can be found on the Agency's website ema.europa.eu/ medicines/human/EPAR/vectibix.
Estonian: Lisateave Vectibixi kohta on ameti veebilehel: ema.europa.eu/ medicines/human/EPAR/vectibix.
English: This summary was last updated in 08-2019.
Estonian: Kokkuvõtte viimane uuendus: 08.2019
English: Vectibix (panitumumab)
Estonian: Vectibix (panitumumaab)
English: The European Medicines Agency decided that Vectibix's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Vectibixi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Vectibix received a conditional marketing authorisation valid throughout the EU on 3 December 2007.
Estonian: Vectibix on saanud müügiloa tingimusliku heakskiidu alusel, mis kehtib kogu ELis, 3. detsembril 2007.
English: This is because growth of these types of cells does not depend on EGFR and they can continue to grow uncontrollably even when EGFR is blocked.
Estonian: See on põhjendatav sellega, et selliste rakkude kasv ei sõltu EGFR-ist ja need jätkavad vohamist isegi juhul, kui EGFR on blokeeritud.
English: This was switched to a full marketing authorisation on 15 January 2015.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 15. jaanuaril 2015.
English: The recommended dose of Vectibix is 6 mg per kilogram body weight given once every two weeks.
Estonian: Vectibixi soovitatav annus on 6 mg kehamassi kg kohta, mida manustatakse 1 kord iga 2 nädala järel.
English: As for all medicines, data on the use of Vectibix are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Vectibixi kasutamise kohta pidevat järelevalvet.
English: What is Vectibix and what is it used for?
Estonian: Mis on Vectibix ja milleks seda kasutatakse?
English: Other information about Vectibix
Estonian: Muu teave Vectibixi kohta
English: Side effects reported with Vectibix are carefully evaluated and any necessary action taken to protect patients.
Estonian: Vectibixi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: The most common side effects with Vectibix (in more than 2 patients in 10) were diarrhoea, nausea (feeling sick), vomiting, constipation, abdominal pain (stomach ache), tiredness, fever, lack of appetite, paronychia (nail bed infection), rash, acneiform dermatitis (skin inflammation resembling acne), pruritus (itching), erythema (reddening of the skin) and dry skin.
Estonian: Vectibixi kõige sagedamad kõrvalnähud (esinenud enam kui 2 patsiendil 10st) olid kõhulahtisus, iiveldus, oksendamine, kõhukinnisus, kõhuvalu, väsimus, palavik, isutus, paronühhia (küünevallipõletik), lööve, aknelaadne dermatiit (aknet meenutav nahapõletik), kihelus, erüteem (nahapunetus) ja nahakuivus.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vectibix have been included in the summary of product characteristics and the package leaflet.
Estonian: Vectibixi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Estonian: Et turustaja esitas vajaliku lisateabe, muudeti tingimuslik müügiluba tavaliseks müügiloaks.
English: The dose may need to be modified if severe skin reactions occur and treatment stopped if the reaction does not get better.
Estonian: Annust tuleb kohandada raskete nahareaktsioonide tekkimisel ning ravi tuleb lõpetada, kui reaktsioon ei vähene.
English: For more information about using Vectibix, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Vectibixi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: In studies, 93% of the patients receiving Vectibix had side effects affecting the skin, although most of these were mild or moderate.
Estonian: Uuringutes tekkisid ligikaudu 93%-l Vectibixi kasutanud patsientidest nahaga seotud kõrvalnähud, kuigi enamik neist olid kerged või mõõdukad.
English: Patients receiving Vectibix also had a longer period of time without their disease getting worse: 6.4 months versus 4.6 months.
Estonian: Vectibixi kasutanud patsientide keskmine progresseerumiseta elumus oli samuti pikem: 6,4 kuud võrreldes 4,6 kuuga.
English: Vectibix was originally given ‘conditional authorisation' because there was more evidence to come about the medicine.
Estonian: Vectibixi müügiluba anti esialgu tingimuslikult, sest selle ravimi toetuseks oodati täiendavaid andmeid.
English: Why is Vectibix approved?
Estonian: Miks Vectibix heaks kiideti?
English: What are the risks associated with Vectibix?
Estonian: Mis riskid Vectibixiga kaasnevad?
English: Vectibix is a medicine for treating colorectal (bowel) cancer that has spread to other parts of the body.
Estonian: Vectibix on ravim, millega ravitakse kolorektaalvähki (jämesoolevähki), mis on levinud organismis ka mujale.
English: As a result, these tumour cells can no longer receive the messages transmitted via EGFR that they need to grow and spread to other parts of the body.
Estonian: Selle tulemusena ei saa kasvajarakud enam EGFR-i kaudu signaale, mida nad vajavad kasvuks ja metastaseerumiseks (organismis mujale levimiseks).
English: It must not be used in patients with interstitial pneumonitis or pulmonary fibrosis (lung diseases).
Estonian: Vectibixi ei tohi kasutada ka patsiendid, kellel on interstitsiaalne pneumoniit või kopsufibroos (teatud kopsuhaigused).
English: The studies show Vectibix can be effective when used alone and together with the standard chemotherapy regimens FOLFOX (a combination of fluorouracil with folinic acid and the cancer medicine oxaliplatin) or FOLFIRI (fluorouracil with folinic acid and a different cancer medicine, irinotecan).
Estonian: Uuringutes tõendati, et Vectibix võib olla efektiivne, kui seda kasutatakse ainuravimina või koos tavapärase FOLFOX-keemiaraviga (fluorouratsiili ja foliinhappe kombinatsioon koos vähiravimi oksaliplatiiniga) või FOLFRI-keemiaraviga (fluorouratsiil koos foliinhappe ja irinotekaaniga (samuti vähiravim)).
English: Treatment with Vectibix should be supervised by a doctor who has experience in the use of cancer therapy.
Estonian: Ravi Vectibixiga peab toimuma vähiravis kogenud arsti järelevalve all.
English: Patients given these combinations lived for an average of 14.8 months and 12.8 months respectively without their disease getting worse.
Estonian: Neid ravikombinatsioone saanud patsientide keskmine progresseerumiseta elumus oli vastavalt 14,8 ja 12,8 kuud.
English: Vectibix must not be used with oxaliplatin-containing chemotherapy in patients whose tumour contains the mutated RAS gene or for whom the RAS status is not known.
Estonian: Vectibixi ei tohi kasutada koos oksaliplatiini sisaldava keemiaraviga patsientidel, kellel kasvaja sisaldab muteerunud RAS-geeni või kellel RAS-staatus ei ole teada.
English: An overview of Vectibix and why it is authorised in the EU
Estonian: Ülevaade ravimist Vectibix ja ELis müügiloa väljastamise põhjendus
English: This study involved patients with either wild-type or mutant RAS whose disease had got worse despite treatments that included a fluoropyrimidine, oxaliplatin and irinotecan.
Estonian: Selles uuringus osalesid nii muteerumata kui ka muteerunud RAS-geeniga patsiendid, kellel haigus oli süvenenud vaatamata fluoropürimidiini, oksaliplatiini ja irinotekaani sisaldavatele raviskeemidele.
English: Patients in this study (there was no comparator treatment) lived for an average of 11.2 months without their disease getting worse.
Estonian: Selles uuringus (võrdlusravi puudus) osalenud patsientide keskmine progresseerumiseta elumus oli 11,2 kuud.
English: For the full list of side effects of Vectibix, see the package leaflet.
Estonian: Vectibixi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Vectibix must not be used in patients who have had a severe or life-threatening hypersensitivity (allergic) reaction to panitumumab or any of the other ingredients in the past.
Estonian: Vectibixi ei tohi kasutada patsiendid, kellel on tekkinud panitumumaabi või selle ravimi mis tahes muu koostisaine suhtes raske või eluohtlik ülitundlikkusreaktsioon (allergiareaktsioon).
English: How does Vectibix work?
Estonian: Kuidas Vectibix toimib?
English: It should only be started after the presence of wild-type RAS has been confirmed by an experienced laboratory using a validated test method.
Estonian: Ravi tohib alustada üksnes pärast seda, kui pädev labor on valideeritud katsemeetodiga kinnitanud muteerumata RAS-geeni olemasolu.
English: It was later confirmed that benefit is limited only to patients with wildtype RAS tumours.
Estonian: Hiljem leidis kinnitust, et kasulik toime avaldub üksnes muteerumata RAS-geeni sisaldavate kasvajatega patsientidel.
English: How is Vectibix used?
Estonian: Kuidas Vectibixi kasutatakse?
English: Several bowel cancer studies have shown that Vectibix is effective at prolonging life or slowing disease progression in patients with ‘wild-type' RAS tumours that have spread.
Estonian: Mitmes jämesoolevähiuuringus tõendati, et Vectibix on efektiivne muteerumata RAS-geeni sisaldava metastaatilise kasvajaga patsientide elu pikendamisel või haiguse progresseerumise aeglustamisel.
English: Panitumumab does not seem to work against tumour cells that contain mutated (abnormal) RAS genes.
Estonian: Näib, et panitumumaab ei toimi muteerunud (ebanormaalseid) RAS-geene sisaldavatele kasvajarakkudele.
English: The active substance in Vectibix, panitumumab, is a monoclonal antibody, a type of protein that has been designed to attach to and block a target called EGFR on certain cells, including some tumour cells.
Estonian: Vectibixi toimeaine panitumumaab on monoklonaalne antikeha (teatud valk), mis on kavandatud seonduma organismi teatud rakkudel, sealhulgas kasvajarakkudel leiduva epidermaalse kasvufaktori retseptoriga (EGFR) ja seda blokeerima.
English: • Patients given Vectibix in combination with FOLFIRI lived for 16.2 months in a study of 1,186 previously treated patients compared with 13.9 months in patients receiving FOLFIRI alone.
Estonian: • Uuringus, milles osales 1186 patsienti, elasid Vectibixi koos FOLFIRI-raviga saanud patsiendid 16,2 kuud ning üksnes FOLFIRI-ravi saanud patsiendid 13,9 kuud.
English: • Patients with wild-type tumours who received Vectibix alone had no disease progression for an average of 16 weeks in a study of 463 patients, compared with 8 weeks in those who did not receive Vectibix and only had supportive care.
Estonian: • Uuringus, milles osales 463 patsienti, oli keskmine progresseerumiseta elumus muteerumata geeni sisaldavate kasvajatega patsientidel, kes kasutasid üksnes Vectibixi, 16 nädalat ning ainult toetavat ravi ilma Vectibixita saanud patsientidel 8 nädalat.
English: What benefits of Vectibix have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vectibixi kasulikkus?
English: It contains the active substance panitumumab.
Estonian: Vectibix sisaldab toimeainena panitumumaabi.